A new study suggests that tuberculosis (TB) tricks the immune system into attacking the body's lung tissue so that the bacteria are allowed to spread to other people.
The concept, as per the University of Southampton research, proposes that current ideas about how tuberculosis develops in patients may be incomplete and that, in fact, infection causes autoimmunity, where the immune system reacts incorrectly to its own tissue.
Tuberculosis kills more people than any other infectious disease, and the causative bacterium, Mycobacterium tuberculosis, is becoming increasingly resistant to antibiotics used to treat the infection.
The Southampton research team conducted a review of published studies and found evidence suggesting that an autoimmunity process develops in TB.
Paul Elkington, who led the project, said, "We are not disputing that the immune system mainly targets the bacteria to fight it off, but we are suggesting that there is more to the story."
"It seems that TB tricks the immune system into damaging our own lung tissue, which therefore makes the person highly infectious through coughing and the TB then spreads by aerosol droplets to other individuals," he said, adding, "There is also a group of patients who develop a range of symptoms, such as eye inflammation, joint inflammation and skin rashes, that are not explained by current TB disease concepts. These symptoms are usually associated with diseases like rheumatoid arthritis and Crohn's disease, which led us to believe autoimmunity plays a key role in the TB disease process."
The researcher highlights that more research is needed to investigate the hypothesis, but if it is proved, the discovery could have major implications for the design of new vaccines and drug treatments.
The Southampton team is now undertaking a programme of work to investigate this new concept. Their approach is to combine the study of cells isolated from TB-infected patients with micro-engineering in 3D in the laboratory to investigate how TB damages the lungs.
The study has been published in Trends in Immunology.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
